Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.
The use of antiretroviral agents and drugs for the treatment and prophylaxis of opportunistic infections has lengthened the survival of persons with AIDS. In the era of multidrug therapy, drug interactions are important considerations in designing effective and tolerable regimens. Clarithromycin has had a significant impact on the treatment of disseminated Mycobacterium avium complex infection, and zidovudine is the best-studied and one of the most widely used antiretroviral agents in this population. We conducted a study to determine the maximally tolerated dose of clarithromycin and the pharmacokinetics of clarithromycin and zidovudine individually and in combination. Mixing studies were conducted to simulate potential interaction in the gastric environment. The simultaneous administration of zidovudine and clarithromycin had little impact on the pharmacokinetics of clarithromycin or of its major metabolite. However, coadministration of zidovudine and clarithromycin at three doses (500 mg orally [p.o.] twice daily [b.i.d.], 1,000 mg p.o. b.i.d., and 2,000 mg p.o. b.i.d.) reduced the maximum concentration of zidovudine by 41% (P < 0.005) and the area under the concentration-time curve from 0 to 4 h for zidovudine by 25% (P < 0.05) and increased the time to maximum concentration of zidovudine by 84% (P < 0.05), compared with zidovudine administered alone. Mixing studies did not detect the formation of insoluble complexes due to chelation, suggesting that the decrease in zidovudine concentrations results from some other mechanism. Simultaneous administration of zidovudine and clarithromycin appears to decrease the levels of zidovudine in serum, and it may be advisable that these drugs not be given at the same time. Drug interactions should be carefully evaluated in persons with advanced human immunodeficiency virus infection who are receiving multiple pharmacologic agents.
Polis
M A
MA
National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland 20982-1880, USA. mpolis@nih.gov
Piscitelli
S C
SC
Vogel
S
S
Witebsky
F G
FG
Conville
P S
PS
Petty
B
B
Kovacs
J A
JA
Davey
R T
RT
Walker
R E
RE
Falloon
J
J
Metcalf
J A
JA
Craft
C
C
Lane
H C
HC
Masur
H
H
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000097:blood* / Q000493:pharmacokinetics; D017291:Clarithromycin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D004347:Drug Interactions; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D015215:Zidovudine / Q000097:blood* / Q000493:pharmacokinetics
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D015215:Zidovudine; D017291:Clarithromycin